<unk> , sold under the brand name Lonsurf, is a fixed-dose combination medication that is used as a third- or fourth-line treatment of metastatic colorectal cancer or gastric cancer, after chemotherapy and targeted therapeutics have failed. It is a combination of two active pharmaceutical ingredients:<unk> , a nucleoside analog, and<unk> , a thymidine phosphorylase inhibitor.<unk>  prevents rapid metabolism of<unk> , increasing the bioavailability of<unk> . The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), feeling sick, tiredness and anemia (low red blood cell counts).
Trifluridine/tipiracil
Decitabine/cedazuridine
Tegafur/gimeracil/oteracil
Trastuzumab/hyaluronidase
Bortezomib/dexamethasone
Trastuzumab emtansine
Daunorubicin/cytarabine
Decitabine